Moderna (NASDAQ:MRNA) Earns Market Perform Rating from William Blair

Moderna (NASDAQ:MRNA)‘s stock had its “market perform” rating restated by research analysts at William Blair in a research note issued to investors on Thursday,RTT News reports.

MRNA has been the subject of several other reports. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research report on Tuesday, February 11th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Argus downgraded Moderna from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Berenberg Bank lifted their target price on Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research report on Thursday, January 16th. Finally, Leerink Partners dropped their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $58.70.

Moderna Stock Down 1.1 %

Shares of MRNA traded down $0.29 during trading hours on Thursday, hitting $24.90. 1,485,493 shares of the company were exchanged, compared to its average volume of 7,207,112. The company has a market cap of $9.63 billion, a price-to-earnings ratio of -2.69 and a beta of 2.23. The firm’s fifty day moving average is $31.10 and its 200 day moving average is $40.37. Moderna has a fifty-two week low of $23.15 and a fifty-two week high of $170.47.

Institutional Investors Weigh In On Moderna

Institutional investors have recently modified their holdings of the company. Allworth Financial LP grew its holdings in Moderna by 17.3% during the 4th quarter. Allworth Financial LP now owns 1,901 shares of the company’s stock worth $73,000 after acquiring an additional 281 shares during the period. Howard Capital Management Inc. grew its stake in Moderna by 3.1% during the fourth quarter. Howard Capital Management Inc. now owns 9,994 shares of the company’s stock worth $416,000 after purchasing an additional 297 shares during the period. Itau Unibanco Holding S.A. increased its holdings in Moderna by 51.2% in the fourth quarter. Itau Unibanco Holding S.A. now owns 1,013 shares of the company’s stock worth $42,000 after purchasing an additional 343 shares in the last quarter. Commonwealth Equity Services LLC lifted its stake in Moderna by 0.5% in the fourth quarter. Commonwealth Equity Services LLC now owns 74,520 shares of the company’s stock valued at $3,099,000 after buying an additional 345 shares during the period. Finally, Larson Financial Group LLC boosted its holdings in shares of Moderna by 39.1% during the 4th quarter. Larson Financial Group LLC now owns 1,266 shares of the company’s stock worth $53,000 after buying an additional 356 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.